Objective: To evaluate the efficacy of liquid embolization agents for treating various hemorrhagic peripheral intracranial aneurysms. Methods: We retrospectively analyzed 38 patients who suffered from hemorrhagic peripheral intracranial aneurysms and were treated with liquid embolization agents. We used the modified Rankin scale for follow-up at 6 months postoperatively, and digital subtraction angiography follow-up was performed 6 months postoperatively. Results: Of the 38 patients (ten of simple peripheral intracranial aneurysms, six of Moyamoya disease (MMD), and 22 of arteriovenous malformation (AVM)), posterior circulation accounted for the most significant proportion (57.9%), followed by anterior circulation (21.1%) and intranidal aneurysms (21.1%). Intraoperative hemorrhage occurred in four cases, postoperative cerebral infarction occurred in four cases, two patients encountered microcatheter retention, and intraoperative thrombosis took place in the basilar artery of a patient with an arteriovenous malformation. A postoperative hemorrhage occurred in only one patient. At 6-month follow-up, 84.2% of patients had good prognosis outcomes, and 13.5% had poor outcomes. Conclusion: Liquid embolization agents are effective for hemorrhagic peripheral intracranial aneurysms; however, safety depends on the subtypes. For peripheral hemorrhagic aneurysms in MMD, the vessel architecture must be carefully evaluated before embolization.
Background. Aneurysmal subarachnoid hemorrhage (aSAH) can impair blood perfusion in brain tissue and cause adverse effects. Microglia, which are the inherent immune cells of the brain, significantly activate and play a role in phagocytosis, anti-inflammatory, proinflammatory, and damage repair in this process. Milk fat globule epidermal growth factor 8 (MFG-E8) is the bridging molecule of this process and mediates the activation and biological effects of microglia. Methods. We obtained cerebrospinal fluid (CSF) from patients with aSAH at various times (the third day, seventh day, and ninth day) as well as from patients in the control cohort. MFG-E8 protein levels in CSF were measured by enzyme-linked immunosorbent assay (ELISA). Meanwhile, we evaluated the GCS and GOS of aSAH patients on admission and on the third day, seventh day, ninth day, and at discharge. Then, we analyzed the association between the levels of MFG-E8 and the changes in GCS and GOS. Results. MFG-E8 expression rose in the early stage on the third day and reached equilibrium around day 7 and day 9. The levels of MFG-E8 on the third day were associated with the change in GOS on the seventh day ( , ) and ninth day ( , ) compared with admission but were not correlated with the change on day 3 or at discharge. The levels of MFG-E8 were not correlated with any change in GCS. Conclusions. We found that aSAH resulted in an upregulation of MFG-E8 in CSF. Moreover, high MFG-E8 levels in the early stage indicated a rapid recovery of mild aSAH patients.
Background: Vertebrobasilar dolichoectasia (VBD) carries high risks of stroke and hemorrhage, yet current treatments remain suboptimal and often compromise critical pontine perforators (PPs). We used computational fluid dynamics (CFD) to evaluate a novel hemodynamically-guided, perforator-sparing reconstruction strategy. Methods: Patient-specific CFD models from 24 VBD patients were compared with 24 age-sex-matched controls and virtual post-intervention models simulating idealized partial anterior basilar artery (BA) lumen reduction to establish hemodynamic optimization targets while preserving posterior wall PPs. Transient simulations quantified pressure, velocity, time-averaged wall shear stress (TAWSS), oscillatory shear index (OSI), and relative residence time (RRT) within the BA and nine modeled PPs per case. Results: Untreated VBD exhibited pathological hemodynamics: elevated aneurysmal pressure (101.73 ± 0.28 vs. 100.59 ± 0.87 mmHg, p < 0.001), flow stasis (velocity: 5.53 ± 3.52 vs. 12.41 ± 3.44 cm/s, p < 0.001), reduced TAWSS (0.007 ± 0.004 vs. 0.03 ± 0.01 Pa, p < 0.001), and increased OSI (0.07 ± 0.04 vs. 0.01 ± 0.00) and RRT (12.73 ± 13.81 vs. 0.33 ± 0.11 /Pa, all p < 0.001). Perforator hemodynamics remained comparable to controls. Virtual reconstruction of BA normalized all aneurysmal parameters toward physiological levels (Post vs. Pre: all p < 0.001) without adversely affecting hemodynamics in the modeled PPs under the assumptions of the CFD framework. Strong correlations existed between BA volume and adverse hemodynamics, with therapeutic benefits approaching saturation at about 250 mm 3 . Conclusion: This in silico study demonstrates that perforator-sparing partial reconstruction can normalize VBD’s pathological hemodynamics without adversely affecting hemodynamics in the modeled PPs, and establishes a quantitative framework for future endovascular device development, though clinical translation requires validation through experimental models and prospective trials.